Syndax Pharmaceuticals, Inc

(NASDAQ:SNDX)

Latest On Syndax Pharmaceuticals, Inc (SNDX):

Date/Time Type Description Signal Details
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01N/A
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 02:38 ESTNewsSyndax Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-04 02:40 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:35 ESTNewsSyndax Pharmaceuticals: 2023 Is A Pivotal YearN/A
2023-03-01 01:25 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04N/A
2023-02-27 19:50 ESTNewsSyndax Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-12 14:22 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowN/A
2022-12-17 03:56 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & ExpositionN/A
2022-12-12 19:48 ESTNewsKura Oncology falls, Syndax gains after Phase 1/2 data for leukemia candidatesN/A
2022-12-10 16:27 ESTNewsSyndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain ProspectN/A
2022-12-07 20:58 ESTNewsSyndax Pharmaceuticals prices $150M offeringN/A
2022-12-07 01:27 ESTNewsSyndax Pharma to sell $150M stock in public offeringN/A
2022-12-05 14:27 ESTNewsSyndax receives breakthrough therapy tag for revumenib to treat acute leukemiaN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 08:33 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidanceN/A
2022-11-02 23:19 ESTNewsSyndax Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62N/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 07:37 ESTNewsSyndax Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-13 12:56 ESTNewsKeith Goldan joins Syndax Pharmaceuticals as CFON/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 16:51 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.63N/A
2022-05-09 00:26 ESTNewsSyndax Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 05:11 ESTNewsSyndax Pharmaceuticals: Cash-Rich With 2 Promising DrugsN/A
2022-03-25 00:25 ESTNewsSyndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare ConferenceN/A
2022-03-02 06:49 ESTNewsSyndax appoints former Alnylam executive as new medical chiefN/A
2022-03-02 06:49 ESTNewsSyndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92MN/A
2022-03-02 06:48 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 18:56 ESTNewsSyndax Pharmaceuticals Q4 Earnings PreviewN/A
2022-01-29 06:36 ESTNewsSyndax Pharmaceuticals (SNDX) Investor Presentation - SlideshowN/A
2021-12-23 00:22 ESTNewsSyndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemiaN/A
2021-12-16 14:02 ESTNewsSyndax Pharma raises $75M via stock offeringN/A
2021-12-15 18:28 ESTNewsSyndax Pharmaceuticals drops 6% following underwritten stock offeringN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals EPS misses by $0.35, misses on revenueN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-14 18:13 ESTNewsSyndax Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-04 16:35 ESTNewsSyndax Pharma falls after updating early-stage data for leukemia therapyN/A
2021-10-05 15:59 ESTNewsSyndax Pharma CFO Daphne Karydas to resign to pursue another opportunityN/A
2021-09-28 02:06 ESTNewsIncyte and Syndax in pact for xatilimab targeting immune-related conditionsN/A
2021-08-10 12:01 ESTNewsSyndax Pharmaceuticals EPS beats by $0.28, beats on revenueN/A
2021-08-10 12:00 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 11:59 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:04 ESTNewsSyndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 DataN/A
2021-07-22 02:02 ESTNewsCanopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst actionN/A
2021-07-22 01:35 ESTNewsSyndax shares rise on FDA Fast Track status for leukemia treatment SNDX-5613N/A

About Syndax Pharmaceuticals, Inc (SNDX):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Syndax Pharmaceuticals, Inc
  • Symbol SNDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2016-03-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syndax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 634.74
  • Price/Book (Most Recent Quarter) 4.43
  • Enterprise Value Revenue 542.55
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.19
  • Next Year EPS Estimate -$2.17
  • Next Quarter EPS Estimate -$0.47
  • Operating Margin -4708%
  • Return on Assets -25%
  • Return on Equity -52%
  • Revenue 1.52 million
  • Earnings Per Share -$2.36
  • Revenue Per Share $0.04
  • Gross Profit 1.52 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.16 billion
  • EBITDA -67280000
  • PE Ratio -125.39
  • Analyst Target Price $32.14
  • Book Value Per Share $5.27
View More

Share Statistics

  • Shares Outstanding 48.24 million
  • Shares Float 42.95 million
  • % Held by Insiders 645%
  • % Held by Institutions 78.88%
  • Shares Short 4.93 million
  • Shares Short Prior Month 4.93 million
  • Short Ratio 9.27
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.84
  • 52 Week High $27.12
  • 52 Week Low $8.18
  • 50 Day Moving Average 22.33
  • 200 Day Moving Average 20.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syndax Pharmaceuticals, Inc (SNDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syndax Pharmaceuticals, Inc (SNDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-08$380000-$0.44-$0.5113.23%
2020-09-302020-11-02$N/A-$0.46-$0.43-6.75%
2020-06-302020-08-06$N/A-$0.42-$0.444.76%
2020-03-312020-05-07$379000-$0.56-$0.53-6.65%
2019-12-312020-03-03$380000-$0.44-$0.43-1.31%
2019-09-302019-11-07$379000-$0.41-$0.4813.92%
2019-06-302019-08-07$379000-$0.47-$0.470.76%
2019-03-312019-05-06$379000-$0.53-$0.554.14%
2018-12-312019-03-07$379000-$0.70-$0.64-9.43%
2018-09-302018-11-05$379000-$0.68-$0.7610.21%
2018-06-302018-08-07$379000-$0.74-$0.8916.94%
2018-03-312018-05-08$379000-$0.79-$0.9517.15%
2017-12-312018-03-05$1.19 million-$0.80-$0.77-3.67%
2017-09-302017-11-07$305000-$0.68-$0.8216.63%
2017-06-302017-08-10$305000-$0.70-$0.8214.83%
2017-03-312017-05-08$305000-$0.71-$0.710.56%
2016-12-312017-03-02$305000-$0.59-$0.7419.79%
2016-09-302016-11-10$305000-$0.84-$0.82-2.78%
2016-06-302016-08-09$305000-$0.47-$0.5412.18%
2016-03-312016-05-16$305000-$0.73-$0.48-52.22%

Syndax Pharmaceuticals, Inc (SNDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Syndax Pharmaceuticals, Inc (SNDX) Chart:

Syndax Pharmaceuticals, Inc (SNDX) News:

Below you will find a list of latest news for Syndax Pharmaceuticals, Inc (SNDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syndax Pharmaceuticals, Inc (SNDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-1910CALL0 00TRUE00
2025-09-192.50CALL0 01213.44TRUE00
2025-09-1940CALL0 01002.05TRUE00
2025-09-1950CALL0 0754.71TRUE00
2025-09-1960CALL0 0559.93TRUE00
2025-09-197.58.5CALL0 1537.53TRUE00
2025-09-1990CALL0 0412.54TRUE00
2025-09-19106.05CALL0 17323.14TRUE00
2025-09-19110CALL0 0342TRUE00
2025-09-1912.53.72CALL1 35259.1TRUE3.720
2025-09-19143.13CALL0 1076163.5TRUE00
2025-09-19151.43CALL3 81645.22TRUE1.430
2025-09-19160.8CALL6 22861.51TRUE00
2025-09-1917.50.3CALL10 566272.55FALSE-0.15-0.33
2025-09-19190.1CALL50 108478.83FALSE0.10
2025-09-19200.07CALL101 105289.66FALSE00
2025-09-19210.15CALL0 3184.81FALSE00
2025-09-19220.12CALL0 22672.73FALSE00
2025-09-19230.03CALL20 14115.87FALSE0.030
2025-09-19240.1CALL0 20261.67FALSE00
2025-09-19250CALL0 0733.66FALSE00
2025-09-1910PUT0 00FALSE00
2025-09-192.50PUT0 01398.57FALSE00
2025-09-1940PUT0 00FALSE00
2025-09-1950PUT0 00FALSE00
2025-09-1960PUT0 00FALSE00
2025-09-197.50.35PUT0 2442.98FALSE00
2025-09-1990PUT0 01250.33FALSE00
2025-09-19100.05PUT0 1070212.68FALSE00
2025-09-19110.05PUT0 25154.26FALSE00
2025-09-1912.50.02PUT7 17494.34FALSE0.020
2025-09-19140.5PUT0 764123.82FALSE00
2025-09-19150.1PUT5 64256.86FALSE-0.15-0.6
2025-09-19160.68PUT0 19102.65FALSE00
2025-09-1917.51.65PUT11 18499.54TRUE1.650
2025-09-19190PUT0 0178.71TRUE00
2025-09-19205.1PUT0 1140.13TRUE00
2025-09-19210PUT0 0222.12TRUE00
2025-09-19227.61PUT0 10249.54TRUE00
2025-09-19230PUT0 0187.44TRUE00
2025-09-19240PUT0 0267.07TRUE00
2025-09-19250PUT0 0207.25TRUE00
2025-10-1710CALL0 00TRUE00
2025-10-172.50CALL0 00TRUE00
2025-10-1740CALL0 0460.53TRUE00
2025-10-17511.1CALL0 13315.1TRUE00
2025-10-1760CALL0 0287.5TRUE00
2025-10-177.57.15CALL0 21201.4TRUE00
2025-10-1790CALL0 0192.02TRUE00
2025-10-17106.1CALL0 517137.73TRUE00
2025-10-17110CALL0 0141.49TRUE00
2025-10-1712.53.8CALL0 71482.83TRUE00
2025-10-17142.75CALL15 2274.96TRUE-0.05-0.02
2025-10-17152.05CALL1 247374.02TRUE-0.22-0.1
2025-10-17161.76CALL2 2075.88TRUE1.760
2025-10-1717.50.81CALL1 50660.05FALSE-0.2-0.2
2025-10-17190.6CALL0 21114.94FALSE00
2025-10-17200.47CALL17 513274.34FALSE-0.07-0.13
2025-10-17210.39CALL0 3483.14FALSE00
2025-10-1722.50.45CALL0 2100.16FALSE00
2025-10-17240CALL0 091.71FALSE00
2025-10-17250.15CALL20 333987.2FALSE0.150
2025-10-17300CALL0 0249.08FALSE00
2025-10-1710PUT0 00FALSE00
2025-10-172.50PUT0 00FALSE00
2025-10-1740PUT0 00FALSE00
2025-10-1750.75PUT0 21468.61FALSE00
2025-10-1760PUT0 0980.65FALSE00
2025-10-177.50.02PUT0 349505.77FALSE00
2025-10-1790PUT0 0591.31FALSE00
2025-10-17100.15PUT0 89594.93FALSE00
2025-10-17110.75PUT0 3172.76FALSE00
2025-10-1712.50.25PUT5 285979.96FALSE-0.05-0.17
2025-10-17140.55PUT0 487131.51FALSE00
2025-10-17151.18PUT0 61379.8FALSE00
2025-10-17161.57PUT0 2107.09FALSE00
2025-10-1717.52.5PUT0 20583.58TRUE00
2025-10-17190PUT0 075.37TRUE00
2025-10-17200PUT0 061.55TRUE00
2025-10-17210PUT0 078.74TRUE00
2025-10-1722.50PUT0 079.18TRUE00
2025-10-17240PUT0 0115.55TRUE00
2025-10-17250PUT0 0107.05TRUE00
2025-10-17300PUT0 0159.59TRUE00
2026-01-162.50CALL0 10TRUE00
2026-01-1655.13CALL0 130TRUE00
2026-01-167.58.74CALL0 148114.76TRUE00
2026-01-1690CALL0 0126.66TRUE00
2026-01-16106.86CALL0 85580.85TRUE00
2026-01-16116CALL0 496.8TRUE00
2026-01-1612.54.7CALL1 537681.58TRUE4.70
2026-01-16143.8CALL0 4477.64TRUE00
2026-01-16153.6CALL5 141075.33TRUE3.60
2026-01-16163.13CALL2 8575.24TRUE0.160.05
2026-01-1617.52.4CALL2 89471.82FALSE-0.05-0.02
2026-01-16201.6CALL6 42683.43FALSE-0.1-0.06
2026-01-1622.51.18CALL0 24776.01FALSE00
2026-01-16250.85CALL0 55480.98FALSE00
2026-01-16300.51CALL10 15879.93FALSE0.510
2026-01-16350.5CALL0 196167.55FALSE00
2026-01-162.50PUT0 0199.42FALSE00
2026-01-1650.36PUT0 8659.77FALSE00
2026-01-167.50.05PUT0 5169.84FALSE00
2026-01-1690PUT0 0139.18FALSE00
2026-01-16100.45PUT0 14082.86FALSE00
2026-01-16110.97PUT0 4153.8FALSE00
2026-01-1612.51.1PUT0 166295.52FALSE00
2026-01-16142.24PUT0 188.67FALSE00
2026-01-16152.3PUT0 26480.14FALSE00
2026-01-16160PUT0 085.38FALSE00
2026-01-1617.53.67PUT5 22081.24TRUE3.670
2026-01-16200PUT0 076.4TRUE00
2026-01-1622.50PUT0 686.54TRUE00
2026-01-16250PUT0 082.72TRUE00
2026-01-16300PUT0 0112.02TRUE00
2026-01-16350PUT0 0117.77TRUE00
2026-04-1750CALL0 0150.16TRUE00
2026-04-1760CALL0 067.07TRUE00
2026-04-1777.8CALL0 1120.86TRUE00
2026-04-1780CALL0 0102.11TRUE00
2026-04-1790CALL0 0110.48TRUE00
2026-04-17107.6CALL0 189.02TRUE00
2026-04-17110CALL0 081.65TRUE00
2026-04-17126CALL2 074.41TRUE60
2026-04-17130CALL0 080.19TRUE00
2026-04-17145.8CALL0 375.54TRUE00
2026-04-17154.3CALL2 3571.57TRUE4.30
2026-04-17163.6CALL100 5375.5TRUE-0.2-0.05
2026-04-17170CALL0 074.71FALSE00
2026-04-17183.1CALL0 1176.21FALSE00
2026-04-17190CALL0 076FALSE00
2026-04-17202.7CALL23 4675.18FALSE0.050.02
2026-04-17210CALL0 096.13FALSE00
2026-04-17251.5CALL0 1187.7FALSE00
2026-04-17300CALL0 098.69FALSE00
2026-04-1750PUT0 0213.22FALSE00
2026-04-1760PUT0 0202.13FALSE00
2026-04-1770PUT0 0170.74FALSE00
2026-04-1780PUT0 0130.81FALSE00
2026-04-1790PUT0 0144.53FALSE00
2026-04-17100PUT0 0114.34FALSE00
2026-04-17110PUT0 0111.09FALSE00
2026-04-17120PUT0 093.48FALSE00
2026-04-17131.95PUT0 1100.45FALSE00
2026-04-17142.4PUT0 264.07FALSE00
2026-04-17152.93PUT0 1257.4FALSE00
2026-04-17163.6PUT0 369.13FALSE00
2026-04-17170PUT0 070.88TRUE00
2026-04-17180PUT0 075.74TRUE00
2026-04-17195.52PUT0 379.29TRUE00
2026-04-17200PUT0 075.22TRUE00
2026-04-17210PUT0 069.5TRUE00
2026-04-17250PUT0 076.14TRUE00
2026-04-17300PUT0 081.33TRUE00

Latest SNDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST3$15.6
Jun 13, 2022 7:59 PM EST4$15.6
Jun 13, 2022 7:59 PM EST1$15.6
Jun 13, 2022 7:59 PM EST100$15.61
Jun 13, 2022 7:59 PM EST45$15.61

Syndax Pharmaceuticals, Inc (SNDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2019-09-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395937/000000000019013216/0000000000-19-013216-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000021545719006549/0000215457-19-006549-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720006818/0000834237-20-006818-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720010194/0000834237-20-010194-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221919000254/0000902219-19-000254-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221920000308/0000902219-20-000308-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266419001816/0000902664-19-001816-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266420000971/0000902664-20-000971-index.htm
2020-11-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000091957420006675/0000919574-20-006675-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518001976/0000921895-18-001976-index.htm
2018-11-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518003173/0000921895-18-003173-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189519000467/0000921895-19-000467-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189520000574/0000921895-20-000574-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359419000160/0001013594-19-000160-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359420000127/0001013594-20-000127-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/0001140361-18-018005-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018007/0001140361-18-018007-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312518197997/0001193125-18-197997-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519034379/0001193125-19-034379-index.htm
2019-03-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519088951/0001193125-19-088951-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312519092679/0001193125-19-092679-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519092701/0001193125-19-092701-index.htm
2019-08-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1395937/000119312519235283/0001193125-19-235283-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395937/000119312519239953/0001193125-19-239953-index.htm
2019-09-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519242045/0001193125-19-242045-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519265254/0001193125-19-265254-index.htm
2020-02-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312520022917/0001193125-20-022917-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312520023646/0001193125-20-023646-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520037637/0001193125-20-037637-index.htm
2020-05-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520139263/0001193125-20-139263-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002680/0001562180-18-002680-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002681/0001562180-18-002681-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002682/0001562180-18-002682-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002683/0001562180-18-002683-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002684/0001562180-18-002684-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002685/0001562180-18-002685-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004047/0001562180-18-004047-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004048/0001562180-18-004048-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/0001562180-18-004049-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004050/0001562180-18-004050-index.htm
2018-11-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000852/0001562180-19-000852-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/0001562180-19-000853-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000854/0001562180-19-000854-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000855/0001562180-19-000855-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/0001562180-19-000856-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/0001562180-19-002023-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003487/0001562180-19-003487-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003488/0001562180-19-003488-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003489/0001562180-19-003489-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003490/0001562180-19-003490-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/0001562180-19-003491-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003492/0001562180-19-003492-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003880/0001562180-19-003880-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001228/0001562180-20-001228-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/0001562180-20-001229-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001230/0001562180-20-001230-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001231/0001562180-20-001231-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001232/0001562180-20-001232-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001233/0001562180-20-001233-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/0001562180-20-001234-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001235/0001562180-20-001235-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/0001562180-20-001236-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001237/0001562180-20-001237-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-07-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005102/0001562180-20-005102-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018004520/0001564590-18-004520-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/0001564590-18-004911-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018011784/0001564590-18-011784-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/0001564590-18-012378-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018014349/0001564590-18-014349-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018019907/0001564590-18-019907-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018020483/0001564590-18-020483-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/0001564590-18-020504-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018023593/0001564590-18-023593-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018026817/0001564590-18-026817-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018026892/0001564590-18-026892-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019002676/0001564590-19-002676-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/0001564590-19-006772-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019006777/0001564590-19-006777-index.htm
2019-03-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019008313/0001564590-19-008313-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019014263/0001564590-19-014263-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019015972/0001564590-19-015972-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/0001564590-19-017318-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019022241/0001564590-19-022241-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019024625/0001564590-19-024625-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030050/0001564590-19-030050-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019030067/0001564590-19-030067-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/0001564590-19-030084-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019036518/0001564590-19-036518-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019041712/0001564590-19-041712-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/0001564590-19-041719-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019045581/0001564590-19-045581-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020004037/0001564590-20-004037-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020005551/0001564590-20-005551-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020008426/0001564590-20-008426-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/0001564590-20-009016-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019694/0001564590-20-019694-index.htm
2020-04-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020019928/0001564590-20-019928-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019941/0001564590-20-019941-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020020574/0001564590-20-020574-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020020633/0001564590-20-020633-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020022849/0001564590-20-022849-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020022971/0001564590-20-022971-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020031882/0001564590-20-031882-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037719/0001564590-20-037719-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/0001564590-20-037767-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/0001564590-20-037777-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020049638/0001564590-20-049638-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020051287/0001564590-20-051287-index.htm
2019-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395937/999999999519002056/9999999995-19-002056-index.htm
2018-11-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999716026189/9999999997-16-026189-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718004150/9999999997-18-004150-index.htm
2018-06-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718006372/9999999997-18-006372-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718007508/9999999997-18-007508-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718009113/9999999997-18-009113-index.htm
2019-03-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999719002097/9999999997-19-002097-index.htm

Syndax Pharmaceuticals, Inc (SNDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syndax Pharmaceuticals, Inc (SNDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 645%
Institutional Ownership: 7888%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-03Peter OrdentlichChief Scientific OfficerSell7,500.0015.00112,500.000.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2020-07-06Michael L. MeyersSVP, Chief Medical OfficerBuy3,500.0010,730.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-11-04Michael A MetzgerPresident and COOBuy100,000.007.20720,000.00117,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-09Briggs MorrisonChief Executive OfficerBuy13,200.007.5699,726.0013,200.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2020-02-12Michael A MetzgerPresident and COOBuy15,000.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-11-04Michael A MetzgerPresident and COOSell100,000.0020.312,031,410.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-13Briggs MorrisonChief Executive OfficerBuy7,200.007.2952,516.8020,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2018-10-30Michael L. MeyersSVP, Chief Medical OfficerBuy200.004.79958.002,398.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-10-10Briggs MorrisonChief Executive OfficerBuy11,000.005.4059,400.0031,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-04Briggs MorrisonChief Executive OfficerBuy12,500.008.00100,000.0043,900.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy1,000.004.934,930.007,118.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy104.004.87506.487,222.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2018-04-03Peter OrdentlichChief Scientific OfficerBuy7,500.003.0823,100.007,500.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm